GKOS

Analyst Note: GKOS (Glaukos Corporation)

Date: 2026-06-13 Current Price: $130.68

1. Structural Readiness

Breakout Level: Not yet defined (pending confirmation of the structural base) Current Price: $130.68 Extension: Not yet defined (price is currently within the forming range, not extended above a confirmed breakout)

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED There is no named secular thesis attached to GKOS at this specific date. The investment case is not driven by a broad macro theme (e.g., "aging population" or "biotech renaissance") but is strictly a function of setup quality and business fundamentals. The conviction must be derived entirely from the structural integrity of the price action and the strength of the underlying operational data provided in the evidence block. We do not invent a thesis; we judge the name on its ability to execute its current business plan and the technical readiness of the chart.

3. The Business

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company focused on developing novel "dropless" platform therapies for glaucoma, corneal disorders, and retinal diseases.

Operational Highlights (as of Q1 2026 and FY 2025):

• Revenue Growth & Guidance: Management raised full-year 2026 net sales guidance to $620 million to $635 million (previously $600M–$620M), expecting high single-digit growth for the franchise for the entire year.
• Franchise Performance:
• Glaucoma: Delivered record Q1 2026 net sales of $93.5 million, up 58% year-over-year, driven by the iDose TR implant.
• Corneal Health: Delivered net sales of $21.3 million (up 15% YoY), including $17.7 million from early sales of Fetrexan and Epioxa.
• Commercial Infrastructure: The company has established a site-of-care network via acquired O2N systems, currently serving roughly 65% of the U.S. population, with a pipeline to expand reach to approximately 95%.
• Reimbursement & Payer Access: Pathways are established for more than 100 million covered commercial lives, including agreements with 4 of the 5 largest payers. On April 15, 2026, CMS assigned a permanent HCPCS J-code (J2789) for Epioxa, a critical milestone for commercial reimbursement.
• Product Mix: In 2025, the iStent family, iDose TR, and accessories accounted for 83% of net sales, while iLink therapies accounted for 17%.
• Manufacturing & R&D: The company is building a new 200,000 square foot R&D and manufacturing facility in Huntsville, Alabama, with construction anticipated to begin in 2026.
• Pipeline: A Phase 2 clinical trial for iLution (Demodex blepharitis) commenced in Q4 2025. Management expects to file for a new indication by the end of 2026, targeting approval in Q4 2027.

4. Archetype and Conviction

Archetype: Quality Compounder This classification fits GKOS based on its transition from a pure device company to a hybrid device/pharma model with accelerating revenue growth, expanding commercial reach, and successful product commercialization (Epioxa, iDose TR).

Conviction Stack:

• Thesis Strength: Moderate (Tactical only; no external macro tailwinds).
• Evidence Quality: High. The evidence block is dense with specific, quantitative data points from earnings transcripts and SEC filings (E1–E22) confirming revenue acceleration, payer access, and operational expansion.
• Structural Quality: The "Quality Compounder" label is supported by the financial spine showing a transition from negative EPS (-0.51 FY1) to positive EPS (0.44 FY2), indicating a path to profitability.
• Setup Readiness: Partial. The setup is "Forming." The price is holding above the support line, but the breakout has not fired. This is a positive signal but not a confirmation.
• Rerating Potential: High, contingent on the successful commercial ramp of Epioxa and the expansion of the O2N network. The assignment of the J-code and the 100M+ payer lives provide a strong foundation for multiple expansion if the breakout occurs.

Volatility Context:

• Current ATR: 5.1% (High). This falls within the historical "sweet spot" (4–6%) for structural quality, suggesting sufficient volatility to support a move without being in the "extreme" danger zone (>8%).
• ATR at Breakout: Not yet recorded (pending breakout).

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Further upward revisions to 2026 guidance beyond the $635M ceiling.
• Positive top-line data from the Phase 2 iLution trial.

What Would Invalidate the Case:

• Significant delays in the 2027 approval timeline for new indications.
• Failure to secure additional payer contracts beyond the current 4 of 5 largest payers.

Gaps in Evidence:

• Detailed Financials: While EPS forecasts are available, specific margin data for the new Corneal Health franchise is not detailed beyond sales figures.
• Capex Timing: While the Huntsville facility construction is "anticipated" to begin in 2026, specific capital expenditure schedules or funding sources are not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Raised 2026 guidance to $620M-$635M; record Q1 glaucoma sales of $93.5M (+58% YoY); CMS assigned permanent J-code J2789 for Epioxa; 100M+ covered commercial lives secured. Key risks: Setup remains in "forming" state with no confirmed breakout; high current ATR (5.1%) implies volatility risk; reliance on new product commercialization (Epioxa) for growth; potential delays in 2027 approval timeline. Sizing hint: Position size should reflect the "forming" status; smaller than a confirmed breakout trade, larger than a speculative early-stage entry. Expected path: Management expects continued high single-digit growth and expansion of the O2N network to 95% population reach; financial spine projects a return to positive EPS in FY2. Expected horizon: 6 to 12 months for the structural breakout and thesis validation.